Last 12 months
Inside the activity.
0 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 24, 2022 Filed Jan 27, 2022 02:03 UTC |
SILVERNAIL LAUREN PSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 77,640 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001570562-22-000054 · wf-form4_164324897583655.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,640 Underlying: Common Stock · 77,640 shares Expires 2032-01-25 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:03 UTC |
SILVERNAIL LAUREN PSee Remarks
|
GrantCommon Stock | 53,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-22-000054 · wf-form4_164324897583655.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,967 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:00 UTC |
BLANK SIMONEDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,727 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001570562-22-000046 · wf-form4_164324881157044.xml · derivative · entry 2 BLANK SIMONE · CIK 0001366840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,727 Underlying: Common Stock · 22,727 shares Expires 2032-01-24 F2 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:00 UTC |
BLANK SIMONEDirector
|
GrantCommon Stock | 15,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-22-000046 · wf-form4_164324881157044.xml · nonDerivative · entry 1 BLANK SIMONE · CIK 0001366840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,881 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 24, 2022, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:03 UTC |
MOATAZEDI DAVIDDirector · See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 310,559 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001570562-22-000055 · wf-form4_164324899548076.xml · derivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,559 Underlying: Common Stock · 310,559 shares Expires 2032-01-25 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:03 UTC |
MOATAZEDI DAVIDDirector · See Remarks
|
GrantCommon Stock | 214,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-22-000055 · wf-form4_164324899548076.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,358 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:02 UTC |
Malik VikramDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,727 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001570562-22-000051 · wf-form4_164324891686588.xml · derivative · entry 2 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,727 Underlying: Common Stock · 22,727 shares Expires 2032-01-24 F2 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:02 UTC |
Malik VikramDirector
|
GrantCommon Stock | 15,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-22-000051 · wf-form4_164324891686588.xml · nonDerivative · entry 1 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,292 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 24, 2022, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:01 UTC |
Parschauer Karah HerdmanDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,727 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001570562-22-000050 · wf-form4_164324889718833.xml · derivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,727 Underlying: Common Stock · 22,727 shares Expires 2032-01-24 F2 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:01 UTC |
Parschauer Karah HerdmanDirector
|
GrantCommon Stock | 15,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-22-000050 · wf-form4_164324889718833.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,881 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 24, 2022, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 22:23 UTC |
Stewart BradyDirector
|
GrantCommon Stock | 36,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-22-000012 · wf-form4_164159419678531.xml · nonDerivative · entry 1 Stewart Brady · CIK 0001902893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,508 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of January 5, 2021, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:37 UTC |
Alphaeon 1 LLC10% owner
|
SaleCommon Stock | 2,597,475 | $9.50 | $24,676,012.50 |
DisclosureSEC source: 0001477932-21-006152 · form4.xml · nonDerivative · entry 1 Alphaeon 1 LLC · CIK 0001799102 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,064,871 Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:19 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 51,000 | $10.93 | $557,567.70 |
DisclosureSEC source: 0001387131-21-009158 · eols-form4_082721.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,463,652 Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:21 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 66,000 | $11.02 | $727,405.80 |
DisclosureSEC source: 0001387131-21-009024 · eols-form4_082521.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,412,652 Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:21 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 44,000 | $11.12 | $489,385.60 |
DisclosureSEC source: 0001387131-21-009024 · eols-form4_082521.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,346,652 Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 20:21 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 72,219 | $11.17 | $807,032.88 |
DisclosureSEC source: 0001387131-21-008933 · medytox-form4_082321.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,302,652 Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 22:37 UTC |
Malik VikramDirector
|
SaleCommon Stock | 26,077 | $11.00 | $286,721.83 |
DisclosureSEC source: 0001570562-21-000167 · wf-form4_162993106421148.xml · nonDerivative · entry 1 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,143,701 F1 · price: The shares were sold by Strathspey Crown Holdings Group, LLC ("SCH") in multiple trades at prices ranging from $10.82 to $11.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The reported securities are directly owned by SCH and may be deemed beneficially owned by the Reporting Person as a Managing Partner of SCH. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:21 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 69,781 | $11.03 | $769,775.15 |
DisclosureSEC source: 0001387131-21-008933 · medytox-form4_082321.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,230,433 Read SEC document |
| August 20, 2021 Filed Aug 21, 2021 00:19 UTC |
Malik VikramDirector
|
SaleCommon Stock | 49,878 | $10.61 | $529,315.31 |
DisclosureSEC source: 0001570562-21-000165 · wf-form4_162950516202272.xml · nonDerivative · entry 2 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,169,778 F3 · price: The shares were sold by SCH in multiple trades at prices ranging from $10.34 to $10.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The reported securities are directly owned by SCH and may be deemed beneficially owned by the Reporting Person as a Managing Partner of SCH. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 20:26 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 48,000 | $10.56 | $506,697.60 |
DisclosureSEC source: 0001387131-21-008879 · medytox-form4_081921.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,160,652 Read SEC document |
| August 19, 2021 Filed Aug 21, 2021 00:19 UTC |
Malik VikramDirector
|
SaleCommon Stock | 11,962 | $10.50 | $125,555.54 |
DisclosureSEC source: 0001570562-21-000165 · wf-form4_162950516202272.xml · nonDerivative · entry 1 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,219,656 F1 · price: The shares were sold by Strathspey Crown Holdings Group, LLC ("SCH") in multiple trades at prices ranging from $10.47 to $10.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The reported securities are directly owned by SCH and may be deemed beneficially owned by the Reporting Person as a Managing Partner of SCH. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:26 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 55,000 | $10.51 | $578,110.50 |
DisclosureSEC source: 0001387131-21-008879 · medytox-form4_081921.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,112,652 Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 23:01 UTC |
Malik VikramDirector
|
SaleCommon Stock | 25,000 | $10.44 | $261,012.50 |
DisclosureSEC source: 0001570562-21-000163 · wf-form4_162941403051387.xml · nonDerivative · entry 2 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,231,618 F3 · price: The shares were sold by SCH in multiple trades at prices ranging from $9.92 to $10.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The reported securities are directly owned by SCH and may be deemed beneficially owned by the Reporting Person as a Managing Partner of SCH. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 20:15 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 45,000 | $10.54 | $474,075.00 |
DisclosureSEC source: 0001387131-21-008746 · medytox-form4_081721.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,057,652 Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 23:01 UTC |
Malik VikramDirector
|
SaleCommon Stock | 42,083 | $10.06 | $423,548.56 |
DisclosureSEC source: 0001570562-21-000163 · wf-form4_162941403051387.xml · nonDerivative · entry 1 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,256,618 F1 · price: The shares were sold by Strathspey Crown Holdings Group, LLC ("SCH") in multiple trades at prices ranging from $9.90 to $10.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The reported securities are directly owned by SCH and may be deemed beneficially owned by the Reporting Person as a Managing Partner of SCH. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 20:15 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 70,000 | $10.69 | $748,062.00 |
DisclosureSEC source: 0001387131-21-008746 · medytox-form4_081721.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,012,652 Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 00:24 UTC |
MOATAZEDI DAVIDDirector · See Remarks
|
SaleCommon Stock | 47,737 | $11.35 | $541,738.57 |
DisclosureSEC source: 0001570562-21-000161 · wf-form4_162924625650402.xml · nonDerivative · entry 2 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,072 F2 · price: The shares were sold in multiple trades at prices ranging from $11.156 to $11.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:10 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 65,000 | $11.34 | $737,035.00 |
DisclosureSEC source: 0001387131-21-008661 · medytox-form4_081321.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,942,652 Read SEC document |
| August 13, 2021 Filed Aug 18, 2021 00:24 UTC |
MOATAZEDI DAVIDDirector · See Remarks
|
SaleCommon Stock | 22,708 | $10.66 | $242,071.82 |
DisclosureSEC source: 0001570562-21-000161 · wf-form4_162924625650402.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,809 F1 · price: The shares were sold in multiple trades at prices ranging from $10.65 to $10.725. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:10 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 49,714 | $10.98 | $545,715.55 |
DisclosureSEC source: 0001387131-21-008661 · medytox-form4_081321.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877,652 Read SEC document |
| August 13, 2021 Filed Feb 6, 2023 21:18 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 14,043 | $11.11 | $156,064.07 |
DisclosureSEC source: 0001387131-23-001468 · ownership.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,296,543 F1 · date: Inadvertently filed late due to an administrative error. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.91 to $11.26, inclusive. F4 · ownership.nature: The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership. Read SEC document |
| August 12, 2021 Filed Aug 13, 2021 20:33 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 39,126 | $10.93 | $427,713.69 |
DisclosureSEC source: 0001387131-21-008519 · medytox-form4_081121.xml · nonDerivative · entry 2 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,827,938 Read SEC document |
| August 12, 2021 Filed Feb 6, 2023 21:18 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 23,000 | $10.99 | $252,774.60 |
DisclosureSEC source: 0001387131-23-001468 · ownership.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,282,500 F1 · date: Inadvertently filed late due to an administrative error. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.88 to $11.10, inclusive. The reporting person undertakes to provide to Evolus, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1 to 2. F4 · ownership.nature: The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:33 UTC |
Medytox Inc.10% owner
|
PurchaseCommon Stock, $0.00001 par value per share | 26,160 | $10.77 | $281,737.97 |
DisclosureSEC source: 0001387131-21-008519 · medytox-form4_081121.xml · nonDerivative · entry 1 Medytox Inc. · CIK 0001848514 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,788,812 Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 22:45 UTC |
Avelar RuiSee Remarks
|
SaleCommon Stock | 14,293 | $11.18 | $159,788.59 |
DisclosureSEC source: 0001570562-21-000155 · wf-form4_162880829149055.xml · nonDerivative · entry 1 Avelar Rui · CIK 0001432063 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,810 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $11.1762 to $11.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 23:05 UTC Amendment |
SILVERNAIL LAUREN PSee Remarks
|
SaleCommon Stock | 14,293 | $11.18 | $159,774.30 |
DisclosureSEC source: 0001570562-21-000158 · wf-form4a_162880951243721.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,396 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $11.1762 to $11.3055. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 22:45 UTC |
SILVERNAIL LAUREN PSee Remarks
|
SaleCommon Stock | 14,293 | $11.18 | $159,774.30 |
DisclosureSEC source: 0001570562-21-000156 · wf-form4_162880831776164.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,982 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $11.1762 to $11.3055. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 23:06 UTC Amendment |
Muilenburg CrystalChief Marketing Officer
|
SaleCommon Stock | 5,362 | $11.18 | $59,943.94 |
DisclosureSEC source: 0001570562-21-000159 · wf-form4a_162880954622924.xml · nonDerivative · entry 1 Muilenburg Crystal · CIK 0001848477 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,743 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $11.1762 to $11.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 23:05 UTC Amendment |
MOATAZEDI DAVIDDirector · See Remarks
|
SaleCommon Stock | 41,763 | $11.18 | $466,839.34 |
DisclosureSEC source: 0001570562-21-000157 · wf-form4a_162880948863025.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,517 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $11.1762 to $11.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 22:44 UTC |
Muilenburg CrystalChief Marketing Officer
|
SaleCommon Stock | 5,362 | $11.18 | $59,943.94 |
DisclosureSEC source: 0001570562-21-000154 · wf-form4_162880827076531.xml · nonDerivative · entry 1 Muilenburg Crystal · CIK 0001848477 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,467 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $11.1762 to $11.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 22:44 UTC |
MOATAZEDI DAVIDDirector · See Remarks
|
SaleCommon Stock | 41,763 | $11.18 | $466,839.34 |
DisclosureSEC source: 0001570562-21-000153 · wf-form4_162880824304017.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,043 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $11.1762 to $11.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 26, 2021 Filed Mar 26, 2021 23:05 UTC |
Malik VikramDirector
|
GrantCommon Stock | 18,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-21-000108 · wf-form4_161679989764970.xml · nonDerivative · entry 1 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,724 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of March 26, 2021, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| March 26, 2021 Filed Mar 26, 2021 23:04 UTC |
MOATAZEDI DAVIDDirector · See Remarks
|
GrantCommon Stock | 48,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-21-000107 · wf-form4_161679987502835.xml · nonDerivative · entry 1 MOATAZEDI DAVID · CIK 0001700836 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,280 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of March 26, 2021, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 23:47 UTC |
Muilenburg CrystalChief Marketing Officer
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001570562-21-000073 · wf-form4_161464240247049.xml · derivative · entry 1 Muilenburg Crystal · CIK 0001848477 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of February 25, 2021, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 17:13 UTC |
GILL DAVID NDirector
|
GrantCommon Stock | 19,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-21-000037 · wf-form4_161290876572094.xml · nonDerivative · entry 1 GILL DAVID N · CIK 0001106519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,313 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 5, 2021, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 17:13 UTC |
HAYMAN ROBERTDirector
|
GrantCommon Stock | 19,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-21-000038 · wf-form4_161290878856259.xml · nonDerivative · entry 1 HAYMAN ROBERT · CIK 0001269349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,313 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 5, 2021, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:12 UTC |
FARRELL PETER CDirector
|
GrantCommon Stock | 19,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-21-000036 · wf-form4_161290873618832.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,313 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 5, 2021, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:13 UTC |
Malik VikramDirector
|
GrantCommon Stock | 19,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-21-000039 · wf-form4_161290881141578.xml · nonDerivative · entry 1 Malik Vikram · CIK 0001730123 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,713 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 5, 2021, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:12 UTC |
Parschauer Karah HerdmanDirector
|
GrantCommon Stock | 19,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-21-000035 · wf-form4_161290871645474.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,313 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 5, 2021, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| February 05, 2021 Filed Feb 12, 2021 18:24 UTC |
BLANK SIMONEDirector
|
GrantCommon Stock | 19,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-21-000045 · wf-form4_161317226111527.xml · nonDerivative · entry 1 BLANK SIMONE · CIK 0001366840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,313 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 5, 2021, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.